MDT-AP-2283
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- sex
- M
- new_clusters
- C5
- umap1_2d
- 5.616712713
- umap2_2d
- 6.358717415
- umap1_3d
- 2.739683905
- umap2_3d
- 0.007270547
- umap3_3d
- -2.948540013
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.440
- IL6_JAK_STAT3_SIGNALING+0.420
- INFLAMMATORY_RESPONSE+0.380
- COAGULATION+0.370
- XENOBIOTIC_METABOLISM+0.350
- INTERFERON_GAMMA_RESPONSE+0.340
- COMPLEMENT+0.300
- KRAS_SIGNALING_DN+0.300
- MYOGENESIS+0.270
- TNFA_SIGNALING_VIA_NFKB+0.250
Top 10 suppressed
- E2F_TARGETS-0.710
- G2M_CHECKPOINT-0.690
- MYC_TARGETS_V1-0.680
- MYC_TARGETS_V2-0.620
- MITOTIC_SPINDLE-0.450
- UNFOLDED_PROTEIN_RESPONSE-0.420
- MTORC1_SIGNALING-0.360
- WNT_BETA_CATENIN_SIGNALING-0.360
- DNA_REPAIR-0.340
- TGF_BETA_SIGNALING-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_KN92S7YQ | Med | Medulloblastoma | 0.919 |
| 2 | MDT-AP-0437 | Med | Medulloblastoma | 0.906 |
| 3 | MDT-AP-2888 | Med | Medulloblastoma | 0.898 |
| 4 | BS_0WVJYM9R | pilocytic astrocytoma | — | 0.891 |
| 5 | MDT-AP-2579 | Med | Medulloblastoma | 0.888 |
| 6 | 855f0a82-04de-485d-9613-5ccf08074069 | — | — | 0.885 |
| 7 | MDT-AP-1266 | Med | Medulloblastoma | 0.885 |
| 8 | C3L-02560 | — | cohortA1 | 0.885 |
| 9 | BS_R244Z0WX | pilocytic astrocytoma | — | 0.883 |
| 10 | BS_NYS8TRCB | low-grade glioma | — | 0.876 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.440 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.420 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.380 | Idelalisib | — uncovered |
| COAGULATION | 0.370 | Binimetinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.350 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.340 | Idelalisib | — uncovered |
| COMPLEMENT | 0.300 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.300 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.270 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.250 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.220 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.190 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.180 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.170 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.170 | Inavolisib | — uncovered |
| HYPOXIA | 0.160 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.160 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.150 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.140 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.120 | Temsirolimus | — uncovered |